ARTICLE | Company News
Capsant, VistaGen deal
January 26, 2009 8:00 AM UTC
The partners will co-commercialize tools for high throughput drug discovery and toxicology testing. The tools will combine VistaGen's stem cell biology capabilities with Capsant's OrganDot 3D culture ...